Satisfaction Of Adult Patients With Gummy Smile Treated By Botulinum Toxin A Injection
NCT ID: NCT03186547
Last Updated: 2017-06-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
22 participants
INTERVENTIONAL
2017-06-30
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Lip Repositioning for the Treatment of Excess Gingival Display With and Without Pretreatment With Botox
NCT04030767
Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile
NCT05127018
Effect of Botox Before Modified Lip Repositioning Repositioning Only in Relapse of the Excessive Gingival Display Within One Year
NCT06148961
Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders
NCT06553950
Botulinum Toxin in the Treatment of Gingival Smile
NCT03812965
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Botulinum Toxin A Injection
this group will receive Botulinum Toxin A Injection at doses of 2.5 or 5 IU (depending on the degree of gum exposure) on each side of the nasolabial fold with follow up at at 2,4,8,12 and 24 weeks.
Botulinum Toxin A Injection
adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
Modified Lip Repositioning Surgery
this group will receive Modified Lip Repositioning Surgery with follow up at at 2,4,8,12 and 24 weeks.
Modified Lip Repositioning Surgery
the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum Toxin A Injection
adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
Modified Lip Repositioning Surgery
the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Excessive gingival display more than 3 mm during smiling.
* Patients having hypermobile upper lip with or without (mild / moderate) vertical maxillary excess.
* Patients with normal morphology of clinical crowns.
* Normal lip separation (ILG) at rest
* Medically free subjects.
Exclusion Criteria
* Gummy smile with gingival display more than 8 mm during smiling.
* Severly long face (VME) patients.
* Patients with periodontal disease or gingival hyperplasia .
* Medically compromised patients contraindicated for surgery .
* Pregnant or lactating female patients.
* Patients with inadequate attached gingiva .
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeinab mohamed
principal investigator
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEBD-CU-2017-06-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.